Wilson Disease

Objective neurological endpoints for Wilson disease programs

Neurological Wilson disease produces tremor, dystonia, and coordination deficits that the Unified Wilson Disease Rating Scale (UWDRS) rates ordinally. NeuroQuantix measures these motor features continuously from a brief spiral drawing, for chelation, zinc, and gene therapy programs that need a sensitive neurological endpoint in a rare population.

Published evidence on digitized spiral analysis supports continuous, rater-independent motor measurement; the strength of that evidence for this condition is stated on this page. NeuroQuantix standardizes this evidence into a pre-specified endpoint for your program. Learn more about wilson disease from the NINDS/NIH overview.

Discuss Your Program View Technical Data

Spectral

Tremor

Frequency and amplitude decomposition

Continuous

Dystonia and Coordination

Velocity irregularity, pressure, spatial error

None

Rater Dependence

Computed metrics

Limited

Evidence Status

Scoping review, Wang et al., 2025

Limitations of UWDRS

The The Unified Wilson Disease Rating Scale, Neurological Subscale (UWDRS) is the current gold standard for wilson disease assessment in clinical trials. These are its documented limitations.

The UWDRS neurological subscale is the accepted clinical measure and remains the anchor for neurological Wilson disease trials

Its items are ordinal and observer-rated, so tremor, dystonia, and coordination changes below one scale step go unmeasured

Wilson disease is rare; trials cannot enroll their way past measurement error

Mixed motor phenotypes (tremor, dystonia, parkinsonism, ataxia) are summed into one score, hiding which domain a treatment changed

Published spiral evidence in Wilson disease is limited; the platform is positioned for exploratory endpoint use

The Wilson Disease Measurement Challenge

Wilson disease programs are small by necessity and neurologically heterogeneous by nature. An ordinal composite that sums tremor, dystonia, parkinsonism, and ataxia into one number hides which domain improved and needs more patients than exist to show it. Continuous, domain-separated kinematics measure each feature directly and sit beside the UWDRS as a pre-specified exploratory endpoint.

Clinical Applications

Copper chelation and zinc therapy trials with neurological endpoints

Gene therapy programs for ATP7B as an exploratory neurological endpoint

Natural history studies in neurological Wilson disease

Published Evidence

Evidence from peer-reviewed publications supporting digital kinematic endpoints for wilson disease assessment. View the full evidence base.

Domain-Separated Motor Measurement

Spiral kinematics preserve tremor, velocity, pressure, and spatial error as separate variables, so mixed phenotypes are measured by domain rather than collapsed into a composite.

Scoping review: Wang S, et al. Movement Disorders Clinical Practice, 2025

Statistical Power Advantage

Higher measurement precision translates directly into smaller enrollment requirements. See the full interactive power curve comparison on the NeuroQuantix platform page.

View Power Visualization

Frequently Asked Questions

What are the limitations of the UWDRS for Wilson disease trials?

The UWDRS neurological subscale is observer-rated and ordinal, sums mixed motor phenotypes into one score, and cannot resolve changes smaller than a scale step. In a rare disease those limits set the trial size. It remains the anchor; a continuous kinematic measure beside it adds domain-specific sensitivity.

How does NeuroQuantix measure neurological Wilson disease?

A brief spiral drawing yields tremor spectra, velocity, pressure dynamics, spatial error, and smoothness. Tremor, dystonic irregularity, bradykinesia, and dysmetria are each measured separately rather than summed, and none requires a rater. The metric matched to the expected treatment effect is pre-specified as an exploratory endpoint beside the UWDRS.

Is spiral analysis validated in Wilson disease?

Wilson disease appears in the published spiral literature mapped by the scoping review, but the evidence is thin compared with Parkinson disease and essential tremor. The appropriate use today is an exploratory endpoint or natural history measurement that builds the within-program evidence a rare-disease program needs.